WALTHAM, Mass. / Aug 28, 2023 / Business Wire / AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will participate in the following upcoming investor conferences:
Morgan Stanley 21st Annual Global Healthcare Conference
Fireside Chat: Monday, September 11, 2023 at 4:55 pm ET
H.C. Wainwright 25th Annual Global Investment Conference
Presentation: Tuesday, September 12, 2023 at 12:00 pm ET
A live webcast and archived replay of these presentations will be available on the Investors & Press section of the AlloVir website at https://ir.allovir.com.
About AlloVir
AlloVir is a leading late-clinical stage cell therapy company focused on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company's innovative and proprietary technology platform leverages off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVir's technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio. For more information, visit www.allovir.com or follow us on Twitter/X or LinkedIn.
| Last Trade: | US$0.57 |
| Daily Change: | 0.01 1.91 |
| Daily Volume: | 659,520 |
| Market Cap: | US$65.760M |
November 08, 2024 December 22, 2023 November 02, 2023 August 03, 2023 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
